Latest Conference Coverage

Migraine History Pre-Concussion Linked to Worse Symptoms Post-Injury

Patients with pre-concussion migraines that occurred at a rate of >1 per month had a greater number of concussion symptoms and burden over 12 weeks.

Atogepant Proves Safe Without ALT Elevation in Healthy Participants

Data presented at AHS 2020 suggest that 170-mg oral atogepant (Allergan) was both safe and well-tolerated, setting the stage the continued development in migraine prevention.

Celecoxib Oral Solution Offers Effective Alternative to Triptans in Acute Migraine

Data from a pair of phase 3 studies suggest that the recently approved celecoxib oral solution (Elyxyb; Dr. Reddy’s Laboratories) offers safe and effective acute treatment of episodic migraine.

Jessica Ailani, MD, FAHS: The Staying Power of Telemedicine in Headache

The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital discussed how this year has proved that telemedicine is likely here to stay.

OnabotulinumtoxinA Proves Safe as Migraine Treatment for Pregnant Women

Infants born to pregnant women with chronic migraine who received treatment with onabotulinumtoxinA did not show any physical, intellectual, or social disabilities.

Migraine With Aura Linked to High Risk of Dementia in Later Life

The results help to better understand the unique risk profiles of people with different subtypes of migraine.

Bryan Davis, PsyD, MS: Future Discussion on Masculinity Norms in MS

The clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS Treatment and Research at Cleveland Clinic details the interventions for men with MS and how the study can change the discussion on masculinity norms.

Youth With Migraine Improve Post-Preventive Treatment Regardless of Therapy Continuation

Results from the CHAMP trial of adolescents and children with migraine add to the already active and ongoing discussion surrounding the use of preventives in this population.

Erenumab Shows Sustainable Efficacy in Refractory Episodic Migraine

Over a 2-year stretch, change in monthly migraine days from the double-blind treatment period baseline was sustained in those treated with erenumab.

Combination OnabotulinumtoxinA and CGRP Treatment Safe and Successful in Migraine

Further studies are needed to confirm the additional reductions in monthly headache days observed in patients with migraine who were treated with onabotulinumtoxinA and an add-on CGRP agent.

Ubrogepant Shows Efficacy for Patients With Chronic and Episodic Migraine

Consistent pain relief from all attacks was reported by 27% of patients treated with ubrogepant and 73% experienced relief from at least 1 attack.

Jessica Ailani, MD: New Approvals and Nonpharmacologic Options for Headache

The director of MedStar Georgetown Headache Center and associate professor of neurology at MedStar Georgetown University Hospital spoke to the specific datasets she is anticipating at the AHS 2020 meeting.

Why Learning About Masculine Norms Can Improve MS Care

In Part 1 of this interview, the clinical health psychology fellow at Cleveland Clinic’s Mellen Center for MS Treatment and Research provides in-depth insight on his study evaluating masculinity norms in patients with multiple sclerosis.

Open-Label Extension: BTKI in Relapsing MS Over 108 Weeks

CMSC Data Release: Abstract DXT58 and MS Risk Reduction

Open-Label Extension: Phase 3 OPERA I and II Trials in Relapsing MS

Post Hoc Analysis: Phase 3 EXPAND Trial in Secondary Progressive MS

Primary Results From the ENSEMBLE PLUS Study

Post Hoc Analysis: Phase 3 ASCLEPIOS I and II Trials in Relapsing MS

Ocrelizumab Compared to Glatiramer Acetate and Dimethyl Fumarate for MS

Progressive MS: The 2020 Whitaker Lecture

The Multidisciplinary Theme of CMSC 2020

AHS 2020: What to Expect From the Annual Scientific Meeting

Ahead of sessions kicking off on June 13, Jessica Ailani, MD, FAHS, offers a look into what data, plenary talks, and developments are set to be presented at the upcoming AHS 2020 annual meeting.

Bryan Davis, PsyD, MS: Behavioral Health and CMNI in Treating MS

The clinical health psychology fellow at the Mellen Center for MS Treatment and Research at Cleveland Clinic details the use of behavioral health and potential use of Conformity to Masculine Norms Inventory (CMNI) tool in multiple sclerosis care.

Jessica Ailani, MD: The Ongoing Expansion in Headache Medicine

The AHS fellow, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital spoke to the rapid expansion of headache medicine and what new research will be discussed at AHS 2020.

Jessica Ailani, MD: Plenary Talks at the AHS 2020 Annual Meeting

The AHS fellow, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital discussed what topics the plenary talks will cover at AHS 2020.

Natalizumab Sets Itself Apart From Other MS Treatments

Carrie Hersh, DO, MSc, assistant professor of neurology at the Cleveland Clinic Lerner College of Medicine, discusses recent data on natalizumab as well as what sets it apart from other multiple sclerosis treatments.

Jessica Ailani, MD: What to Expect From the American Headache Society Meeting

The AHS fellow, director of MedStar Georgetown Headache Center, and associate professor of neurology at MedStar Georgetown University Hospital spoke to what to expect from this year’s annual scientific meeting.

Fernando Dangond, MD, MBA: Phase 2 Data on Evobrutinib in MS

Head of Global Clinical Development in Neurology at EMD Serono discussed the findings of a phase 2 assessment of the company’s investigational BTK inhibitor evobrutinib in multiple sclerosis.

Novel BTK Inhibitor Evobrutinib Displays Long-Term Success in MS

The vice president of Global Program Leadership in Neurology and Immunology at EMD Serono discussed the recent long-term phase 2 data on evobrutinib presented at CMSC 2020.